Last updated: June 25, 2026

NILANDRON (nilutamide) Market Dynamics and Financial Trajectory: Exclusivity, Competition, Pricing Pressure, and Revenue Outlook

Executive summary: Nilandron (nilutamide) remains a legacy-only U.S. brand with limited current lifecycle upside because market access depends on narrow prostate cancer use and the drug’s aging patent/exclusivity landscape. Financial trajectory is driven primarily by (1) shrinking demand from substitution by newer androgen-axis therapies and second-generation antiandrogens, (2) pricing and reimbursement compression typical of older oncology agents, and (3) supply and channel stability as generics gain or maintain share in many markets. In the U.S., commercial performance and near-term earnings sensitivity are mainly explained by residual brand volume, payer mix, and competitive prescribing shifts rather than new exclusivity-driven growth.

What is Nilandron (nilutamide) used for and what drives demand?

Nilandron (nilutamide) is an anti-androgen used in prostate cancer, classically in advanced disease settings. Demand is concentrated in oncology prescribing patterns that have increasingly shifted toward agents with broader modern evidence bases and more favorable tolerability profiles.

Key demand drivers

Stage and regimen selection: Legacy anti-androgen use remains tied to clinician preference and patient-specific constraints, but overall regimen share has moved toward androgen receptor pathway inhibitors (ARPIs) and treatment intensification.
Tolerability and monitoring burden: Nilutamide’s adverse effect profile influences uptake, particularly where patients are managed with newer agents that have more standardized monitoring pathways.
Treatment line migration: As advanced prostate cancer treatment evolves, nilutamide’s role is increasingly substituteable.
Generic availability and procurement: Where generics are available at a material discount, hospital formularies and group purchasing organizations typically steer toward lowest net cost options.

How big is the nilutamide opportunity and what are the unit economics benchmarks?

Featured snippet answer: The nilutamide category is structurally limited by aging clinical positioning, low incremental use, and generic substitution dynamics. Revenue opportunity typically tracks with residual branded volume and net price after rebates, not with growth in total treatable patient numbers.

How revenues usually behave in older U.S. brands

Volume erosion from substitution and off-label/regimen shifts.
Net price pressure from payer contracting, markdowns, and wholesaler buying behavior.
Gross-to-net compression from rebate intensity required to maintain formulary access.

Unit economics considerations for legacy oncology brands

Channel stocking risk: Older brands can see discontinuous order patterns, affecting manufacturer production scheduling and working capital.
Payer-driven mix: If formulary status weakens, net price may improve but volume often collapses faster, lowering total revenue.
Inventory and supply continuity: Any supply disruption can temporarily raise realized prices but tends to be followed by normalization as supply stabilizes.

What patent and exclusivity protections apply to Nilandron (nilutamide), and when do they expire?

Nilutamide is a mature molecule. The economic thesis for Nilandron is therefore dominated by whether any remaining composition-of-matter, formulation, or method-of-use protection exists in the relevant markets and whether any pediatric, regulatory, or formulation extensions extend effective exclusivity.

Life-cycle implication

Without current, enforceable exclusivity in key jurisdictions and dosage forms, Nilandron behaves like a late-cycle brand where market share is primarily defended by contracting and supply reliability rather than legal barriers.

Practical takeaway for market modeling

Base-case revenue forecasts should assume ongoing generic substitution and no material exclusivity-driven re-acceleration unless a still-active patent estate is identified that covers a specific formulation/dosing or a protected indication.

What is the Orange Book status of Nilandron (nilutamide) in the U.S.?

Featured snippet answer: For legacy small-molecule oncology brands, Orange Book listings typically show either expired exclusivity or listed patents that no longer block generic approval, leading to widespread generic entry. That status means Nilandron’s revenue depends on net pricing and contracted access rather than statutory FDA exclusivity.

How Orange Book status affects financial trajectory

If Orange Book protection is largely expired:
- Generics can sell once approved without branded licensing economics.
- Brand may still compete on patient and prescriber familiarity, but volume faces systematic erosion.
If there are active, listed patents:
- Expect “launch-over” risk management via litigation or settlement, which may temporarily preserve brand share.

Narrow impact on Nilandron economics

For legacy anti-androgens, even where patents exist, generic competition often continues unless the brand can sustain enforceable barriers and win at the district level.

How many generic versions of nilutamide compete with Nilandron, and what are the launch risks?

Featured snippet answer: In late-cycle small-molecule markets, multiple generic entrants commonly hold share. Launch-over risk depends less on FDA approval timelines and more on settlement status, patent challenges, and contracting behavior.

Competitive entry patterns

Immediate substitution: When generics have “drop-in” interchangeability and favorable pricing, pharmacy and oncology dispensing commonly shift rapidly.
Institutional formulary locks: Hospitals may restrict branded ordering even after physician requests, depending on value-based procurement contracts.
Distribution leverage: Wholesalers can drive brand share down by steering toward lower-cost SKUs.

Commercial risk factors

Price-led contracting: Net price compression accelerates when more low-cost SKUs enter.
Short supply issues: If brand becomes less consistently available, physicians may switch permanently.
Litigation outcomes: Patent wins by generics reduce the brand’s protected time window.

What patent litigation affects Nilandron (nilutamide) and how does it change market share?

Featured snippet answer: Patent litigation typically influences short windows of brand protection and generic entry sequencing. For older drugs, most value is tied to whether any remaining litigation extends exclusivity-like barriers during the last competitive transition rather than creating multi-year revenue uplift.

How litigation flows into financials

If brand wins: Generics delay entry, sustaining higher net price and share.
If generics win or settlements occur: Entry follows an agreed timing, producing immediate share loss and net price declines.
If settlement includes reverse payments: Brand may receive compensation that temporarily offsets volume erosion, but public visibility and durability vary.

Economic model impact for Nilandron

Litigation tends to shift the slope of revenue decline, not reverse it, given generics’ long-run advantage when statutory exclusivity is absent.

How do nilutamide’s competitive dynamics compare with newer anti-androgens and ARPIs?

Nilutamide competes in a therapeutic landscape dominated by more modern androgen-axis agents. These drugs frequently capture greater proportion of clinical decision-making due to:

broader use across line settings,
evidence-driven label positioning,
often more favorable tolerability and monitoring profiles.

Competitive comparison drivers

Clinical preference: ARPIs and second-generation anti-androgens often gain default regimen status.
Safety and tolerability: Patient-specific risk can still favor older agents, but overall preference shifts reduce category growth.
Treatment sequencing: Newer regimens can displace nilutamide earlier in care, limiting residual demand.

Financial implication

Even if nilutamide retains a niche, the unit market typically becomes smaller and more sensitive to net price.

What formulation, method-of-use, and manufacturing patents could still matter for Nilandron?

Featured snippet answer: For legacy drugs, remaining value often stems from niche protected attributes such as specific formulations, dosing regimens, or manufacturing methods. Without such active protections, financial trajectory follows generic penetration.

Patent estate categories to evaluate for residual barriers

Composition of matter: Unlikely to remain relevant for nilutamide due to age of molecule.
Formulation patents: Could include specific excipient systems, controlled-release, or stability-enhanced forms.
Method-of-use patents: Could protect a specific clinical use or patient subpopulation.
Manufacturing process patents: Can block certain generic manufacturing routes but rarely stop all entry unless tightly constrained.

Economic effect

Any active formulation or process protection that covers the branded product presentation can slow full substitution in specific channels.

When does Nilandron lose exclusivity and what does the post-exclusivity phase typically look like financially?

Featured snippet answer: After exclusivity ends, legacy oncology brands usually enter a multi-year decline driven by generic substitution. Net price compresses first in contracted channels, and volume erosion follows as prescribers and institutions normalize to generics.

Typical post-exclusivity trajectory

Year 0-1: Sharp share loss in high-volume channels; net price falls due to contracting.
Year 1-3: Further volume decline or stabilization at a residual niche depending on patient/physician preference and tolerability.
Year 3+: Category becomes largely generic-led; brand becomes a minor supplier unless it retains preferential access or supply reliability.

For Nilandron

The most probable model is a continued decline with periodic volatility tied to supply and contracting rather than a step-change in demand.

What FDA regulatory pathway dynamics influence Nilandron’s competitive threat?

Even for older small molecules, FDA approval pathways shape how quickly generics appear and whether labeling or substitution is frictionless.

Regulatory pathways that matter commercially

ANDA approvals and labeling: Generic labeling that supports full substitution accelerates volume erosion.
Patent certifications (paragraph IV) and stays: Can delay approval depending on litigation outcomes.
Labeling changes affecting interchangeability: If brand labeling is updated with new safety language, substitution patterns can shift slightly.

Commercial impact

The faster generics can be prescribed and filled with minimal friction, the faster Nilandron’s revenue erodes.

How do reimbursement and pricing trends typically affect older oncology brands like Nilandron?

Featured snippet answer: Pricing for late-cycle oncology brands is dominated by contracting and reimbursement pressure. Net realized price typically falls even when list price may hold temporarily.

Reimbursement levers

PBM and payer preferred drug lists: Generics are typically preferred, pushing brand toward non-preferred status.
340B and institutional procurement: Can reduce demand for the brand if institution switches to low-cost equivalents.
Value-based arrangements: Some legacy brands retain managed entry agreements if they can offer predictable supply or patient support.

Revenue sensitivity

Revenue is highly elastic to net price and share changes, not to patient population growth.

What is the revenue exposure of Nilandron under realistic generic entry scenarios?

Featured snippet answer: Revenue exposure is primarily to share losses rather than to new patient growth. Scenarios should focus on the speed and depth of generic penetration in institutional channels.

Scenario framework (directional)

Best case: Brand maintains niche prescribing; limited additional generic penetration; modest net price decline.
Base case: Continued erosion in contracted channels; replacement by generics; revenue declines steadily.
Worst case: Rapid formulary downgrades and aggressive pricing by generics; abrupt volume step-down.

Key sensitivity variables

Time-to-formulary access changes
Net price after rebates
Supply continuity and fill rates
Prescriber persistence versus conversion at next refill

Which companies typically supply generic nilutamide, and how does that change competitive intensity?

Generic supply intensity affects price and availability. For legacy molecules, competitive intensity increases with:

number of ANDA holders,
ability to sustain low-cost manufacturing,
distribution agreements.

Financial consequence

More suppliers generally increases price competition and reduces branded share further, especially in institutional contracts.

What manufacturing and supply chain/IP barriers could affect Nilandron availability?

For small molecules, manufacturing barriers are often less decisive than for biologics, but they still matter.

Supply-chain drivers

API availability and cost volatility
Quality/regulatory compliance history
Contract manufacturing capacity

IP-linked manufacturing issues

If any process patents remain active (less likely for nilutamide), generic manufacturing could face injunction risk in limited scopes, slowing specific entrants.

Key Takeaways

Nilandron’s financial trajectory is structurally constrained by legacy positioning in prostate cancer and ongoing generic substitution dynamics.
Market demand is driven by narrow regimen persistence, not by expanding indication breadth.
In most realistic late-cycle scenarios, Nilandron revenue declines follow a pattern dominated by net price compression, formulary shifts, and residual niche volume, with litigation affecting timing rather than restoring long-run growth.
The dominant business question is whether any active patent estate (formulation, method-of-use, or manufacturing) continues to defend meaningful share in specific markets; absent that, the category remains generic-led.

FAQs

Do generic nilutamide and Nilandron have the same dosing and interchangeability in practice?
How do paragraph IV challenges for nilutamide typically affect generic entry timing?
What payer formulary dynamics most influence Nilandron net pricing and volume?
Is nilutamide’s clinical role shrinking faster in community oncology or academic centers?
How does supply continuity for older oncology small molecules impact real-world switching to generics?

References (APA)

No sources cited.

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	6
Patent Applications:	5,099
Drug Prices:	Drug price information for NILANDRON
What excipients (inactive ingredients) are in NILANDRON?	NILANDRON excipients list
DailyMed Link:	NILANDRON at DailyMed

Sponsor	Phase
Southwest Oncology Group	Phase 3
NRG Oncology	Phase 2/Phase 3
National Cancer Institute (NCI)	Phase 2/Phase 3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Advanz Pharma	NILANDRON	nilutamide	TABLET;ORAL	020169-001	Sep 19, 1996		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Advanz Pharma	NILANDRON	nilutamide	TABLET;ORAL	020169-002	Apr 30, 1999		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

NILANDRON Drug Patent Profile

When do Nilandron patents expire, and when can generic versions of Nilandron launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nilandron

AI Deep Research

Questions you can ask:

Summary for NILANDRON

Recent Clinical Trials for NILANDRON

US Patents and Regulatory Information for NILANDRON